Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome

Clinical trial NCT06967038 · RECRUITING

Trial details

NCT number: NCT06967038
Sponsor: Bangdong Gong
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Primary Sjogren's Syndrome Lymphoma

Start date: 2025-02-28
Primary completion: 2027-10-31
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.